Faculty Collaboration Database

1. Inhibiting MEK in MAPK pathway-activated myeloma. Heuck CJ, Jethava Y, Khan R, van Rhee F, Zangari M, Chavan S, Robbins K, Miller SE, Matin A, Mohan M, Ali SM, Stephens PJ,Ross JS, Miller VA, Davies F, Barlogie B, Morgan G. Leukemia. 2016, Apr;30(4) (doi:10.1038): 976-80.

2. A Case of Cardiac Light Chain Deposition Disease in a Patient with Solitary Plasmacytoma. Mohan M, Gokden M, Gokden N, Schinke C. Am J Case Rep. 2016, Mar; 17(2016 Mar 18): 173-6.

3. Lasiodiplodia species fungal osteomyelitis in a multiple myeloma patient. Mohan M, Shalin SC, Kothari A, Rico JC, Caradine K, Burgess M.Transplant infectious disease Journal. 2016, Jun; doi:10.1111/tid.125 (doi: 10.1111/tid.125)

4. Tandem Autologous Stem Cell Transplantation in Patients with Persistent Bone Marrow Minimal Residual Disease Post First Transplantation in Multiple Myeloma. Meera Mohan, Sravani Gundarlapalli, Aniko Szabo, Naveen Yarlagadda, Yetunde Ogunsesan, Lakshmi Yarlagadda, Nishant Thalambedu, Hussain Munawar, Monica Graziutti, Daisy Alapat, Sharmilan Thanendrarajan, Samer Al Hadidi, Maurizio Zangari, Frits van Rhee, and Carolina Schinke. Am J Hematol. 2022 Mar 14. doi: 10.1002/ajh.26530

5. Update on the optimal use of bortezomib in the treatment of multiple myeloma.Mohan M, Matin A, Davies FE.Cancer Manag Res. 2017 Mar 2;9:51-63.doi:10.2147/CMAR.S105163.

6. Gastrointestinal histoplasmosis in a patient after autologous stem cell transplant for multiple myeloma.Mohan M, Fogel B, Eluvathingal T, Schinke C, Kothari A.Transpl Infect Dis. 2016 Dec; 18(6):939-941. doi: 10.1111/tid.12619. Epub 2016 Nov.

7. Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients with Multiple Myeloma.Mohan M, Samant RS, Yoon D, Buros AF, Branca A, Montgomery CO, Nicholas R, Suva LJ, Morello R, Thanendrarajan S, Schinke C, Yaccoby S, van Rhee F, Davies FE, Morgan GJ, Zangari M. J Bone Miner Res. 2017 Jun;32 6):1261-1266. doi: 10.1002/jbmr.3111. Epub 2017 Mar 27

8. Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. Mohan M, Buros A, Mathur P, Gokden N, Singh M, Susanibar S, Jo Kamimoto J, Hoque S, Radhakrishnan M, Matin A, Davis C, Grazziutti M, Thanendrarajan S, van Rhee F, Zangari M, Davies F, Morgan G, Epstein J, Barlogie B, Schinke C. Am J Hematol. 2017 Aug;92(8):739-745. doi: 10.1002/ajh.24756. Epub 2017 Jun 1.

9. The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype. Schinke C, Hoering A, Wang H, Carlton V, Thanendrarajan S, Deshpande S, Patel P, Molnar G, Susanibar S, Mohan M, Mathur P, Radhakrishnan M, Hoque S, Jo Kamimoto J, Grazziutti M, van Rhee F, Zangari M, Insuasti-Beltran G, Alapat D, Post G, Yaccoby S, Epstein J, Rasche L, Johnson S, Moorhead M, Willis T, Barlogie B, Walker B, Weinhold N, Davies FE, Morgan GJ. Haematologica. 2017 May 18. pii: haematol.2017.165217. doi:10.3324/haematol.2017.165217.

10. Bacteremias Following Autologous Stem Cell Transplantation for Multiple Myeloma: Risk Factors and Outcomes. Meera Mohan, MD, Sandra Susanibar-Adaniya, MD, Amy Buros, PhD, Juan Carlos Rico Crescencio, MD, Mary J Burgess, M, Katherine Lusardi, PharmD, BCPS-AQ ID, Faith Davies, MBBCh, MRCP, MD, FRCPath, Gareth Morgan, M.D. FRCP, FRCPath, Ph.D, Frits Vanrhee, MD, PhD, Maurizio Zangari, MD, Carolina Schinke, MD, Sharmilan Thanendrarajan, MD, PhD and Atul Kothari, MD. Transpl Infect Dis. 2019 Apr; 21(2): e13052. doi: 10.1111/tid.13052. Epub 2019 Feb 15

11. Effect of low dose bortezomib on bone formation in smouldering multiple myeloma. Hildebrandt GC, Berno T, Gurule A, Mohan M, Yoon D, Salama M, Zangari M. Br J Haematol. 2018 Mar 24. doi: 10.1111/bjh.15095.

12. Daratumamab in High-Risk Relapse/Refractory Myeloma Patients: Effect of 1q21 Duplication and GEP70 Status. Meera Mohan, MD, Niels Weinhold PhD, Frits van Rhee, MD, Carolina Schinke, MD, Sharmilian Thanedrarajan, MD, Leo Rasche, MD, Jeffrey Sawyer, MD, Erming Tian, PhD, Faith Davies, MD, Gareth Morgan, MD, Maurizio Zangari, MD.Br J Haematol. 2019 Dec 9 doi: 10.1111/bjh.16292

13. Draft Genome Sequences of 48 Vancomycin-Resistant Enterococcus faecium Strains Isolated from Inpatients with Bacteremia and Urinary Tract Infection. Udaondo Z, Wongsurawat T, Jenjaroenpun P, Anderson C, Lopez J, Mohan M, Tytarenko R, Walker B, Nookaew I, Ussery D, Kothari A, Jun SR. Microbiol Resour Announc. 2019 Apr 11;8(15). pii: e00222-19. doi: 10.1128/MRA.00222-19.

14. Complete Genome Sequences of Four Isolates of Vancomycin-Resistant Enterococcus faecium with vanA Gene from Two Patients with Prolonged Bacteremia Piroon Jenjaroenpun, Thidathip Wongsurawat, Zulema Udaondo, Courtney Anderson, James Lopez, Meera Mohan, Ruslana Tytarenko, Brian Walker, Intawat Nookaew, David Ussery, Atul Kothari, Se-Ran Jun Microbiol Resour Announc. 2020 Feb 6;9(6). pii: e01380-19. doi: 10.1128/MRA.01380-19.

15. Nivolumab-Induced Immune-Mediated Neurotoxicity in Hodgkin’s Lymphoma James Lopez, MD, Naveen Yarlagadda, MD, Zaid Gheith, MD, Meera Mohan, MD, Appalanaidu Sasapu, MD October 2019, Proceedings (Baylor University. Medical Center) DOI:10.1080/08998280.2019.1668719

16. Genomic Analysis of Primary Plasma Cell Leukemia reveals complex Structural Alterations and High- Risk Mutational Patterns Carolina Schinke, Eileen M. Boyle, Cody Ashby, Yan Wang, Valeriy Lyzogubov, Christopher Wardell, Pingping Qu, Shayu Deshpande, Katie Ryan, Sharmilan Thanendrarajan, Meera Mohan, Naveen Yarlagadda, Maliha Khan, Samrat Roy Choudhury, Maurizio Zangari, Frits van Rhee, Faith Davies, Bart Barlogie, Gareth Morgan and Brian A. Walker Blood Cancer J. 2020 Jun 19;10(6):70. doi: 10.1038/s41408-020-0336-z.PMID: 32555163

17. Two Cases of Vancomycin Resistant Enterococcus faecium Bacteremia with Development of Daptomycin Resistant Phenotype and its Detection Using Oxford Nanopore Sequencing Zulema Udaondo, Piroon Jenjaroenpun, Thidathip Wongsurawat, Erik Meyers, Courtney Anderson, James Lopez, Meera Mohan, Ruslana Tytarenko, Brian Walker, David Ussery, Atul KothariSe-Ran Jun Open Forum Infectious Diseases, 23 May 2020

18. Bone remineralization Of Lytic Lesions in Multiple Myeloma--The Arkansas Experience. Meera Mohan, Erming Tian, Shivang Desai, Frits van Rhee, Sharmilan Thanendrarajan, Carolina Schinke, Larry J. Suva, Shobhit Sharma, Manoj Kumar, Mohamed Milad, Samantha Kendrick, Maurizio Zangari Bone. 2021 Feb 5;115876. doi: 10.1016/j.bone.2021.115876

19. Refractory Hypercalcemia in Multiple Myeloma: An Infectious Etiology. James Lopez, MD; Mihir Raval MD, MPH; Meera Mohan MD. MS Transpl Infect Dis 05 June 2020; doi.org/10.1111/tid.13354

20. Salvage Second Transplantation in Relapsed Multiple Myeloma Binod Dhakal, Anita D’Souza, Ariel Kleman, Saurabh Chhabra, Meera Mohan, Parameswaran Hari, Leukemia 2020 Aug 4. doi: 10.1038/s41375-020-1005-8

21. Clinical Characteristics of Testicular Extramedullary Involvement in Multiple Myeloma Meera Mohan MD, MS; Naveen Yarlagadda MD, MS; Aniko Szabo PhD; Sergio Pina Oviedo MD; Carolina Schinke MD, Am J Hematol. 2020 Dec 18. doi: 10.1002/ajh.26072

22. Clinical Implications of Loss of Bone Marrow Minimal Residual Disease (MRD) Negativity in Multiple Myeloma, Meera Mohan MD MS, Samantha Kendrick PhD, Naveen Yarlagadda MD, MS, Dinesh Atwal MD, Yadav Pandey MD, Arya Roy MD, Richa Parikh MD, James Lopez MD, Sharmilan Thanendrarajan MD, Carolina Schinke MD, Daisy Alapat MD, Jeffery Sawyer PhD, Erming Tian PhD Frits van Rhee MD PhD, Maurizio Zangari MD Submitted to Blood Advances (In Press)

23. Interactions between Cardiology and Oncology Drugs in Precision Cardio-Oncology Sailaja Kamaraju MD*, Meera Mohan MD*, Svetlana Zaharova, Deval Gor, Brianna Wallace, Joseph McGraw, James Lokken, John Tierney, Elizabeth Weil, Olubadewa Fatunde MD MPH, Sherry-Ann Brown, MD PhD, Clinical Science (2021)00 1–19.doi.org/10.1042/CS20200309

24. Feasibility of outpatient stem cell transplantation in multiple myeloma and risk factors that predispose for hospital admission. Kristin Larsen, Meera Mohan, Clyde Bailey, Kerri Hill, Horace Spencer, Mathew Kottarathara, Richa Parikh, Shadiqul Hoque, Erra Amani, Angel Mitma, Pankaj Mathur, Guido Tricot, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee and Carolina Schinke Submitted to Biology of Blood and Marrow Transplantation (under review)

25. Multiple Myeloma–Time for a second major paradigm shift, Meera Mohan MD MS, Parameswaran Hari MD MS, Binod Dhakal MD MS. JCO Oncology Practice doi:10.1200/OP.21.00032

26. Persistent Bone Marrow Minimal Residual Disease in Multiple Myeloma is associated with Dismal Outcome. Meera Mohan MD MS, Aniko Szabo PhD, Naveen Yarlagadda MD MS, Sravani Gundarlapalli, Sharmilan Thanendrarajan MD, Carolina Schinke MD, Daisy Alapat MD, Frits van Rhee MD PhD, Maurizio Zangari MD, Am J Hematol. 2021 May 29. doi: 10.1002/ajh.26255

27. Combinatorial Treatment for Unresectable Unicentric Castleman Disease Meera Mohan, MD; James C Meek, MD; Mary Elizabeth Meek, MD; Ralph Broadwater, MD; Daisy Alapat, MD; Frits van Rhee, MD, PhD. European Journal of Hematology 09 July 2021 https://doi.org/10.1111/ejh.13685

28. Outcomes of VDPACE with an Immunomodulatory Agent (IMiD) as a Salvage Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) with Extramedullary Disease (EMD) Al-Ola Abdallah, Ghulam Rehman Mohyuddin, Nusheen Ahmed, Meera Mohan, Wei Cui, Leyla Shune, Zahra Mahmoudjafari, Joseph McGuirk, Siddhartha Ganguly, Shebli Atrash European Journal of Hematology 16 September 2021 https://doi.org/10.1002/jha2.275

29. Pulmonary Lymphangitic Spread of Multiple Myeloma as Early Relapse Post Autologous Stem Cell Transplantation. Bicky Thapa, MD, Gulrayz Ahmed, MD, Meera Mohan, MD, MS, Volodymyr Shponka, Parameswaran Hari, MD, MS Case reports in Hematology, Volume 2021, Article ID 5590975, doi.org/10.1155/2021/5590975

30. Long term follow up of Newly Diagnosed Multiple Myeloma (NDMM) patients treated with Pembrolizumab consolidation post autologous stem cell transplantation (ASCT) Meera Mohan MD, MS; Aniko Szabo PhD; Binod Dhakal MD, MS;Saurabh Chhabra MD, MS; Parameswaran Hari MD, MS; Anita D’Souza MD, MS. Leukemia Research, Volume 109, Oct 2021 doi.org/10.1016/j.leukres.2021.106648

31. Salvage Autologous Stem Cell Transplantation in Daratumumab refractory Multiple Myeloma Lakshmi Yarlagadda, Sravani Gunarlapalli, Richa Parikh, Reid Landes, Mathew Kottarathara, Yetunde Ogunsesan, Shadiqul Hoque, Angel Mitma, Clyde Bailey, Kerri Hill, Sharmilan Thanendrarajan, Monica Graziutti, Meera Mohan, Maurizio Zangari, Frits van Rhee Guido Tricot, and Carolina Schinke Cancers 2021, 13, 4019. https://doi.org/10.3390/cancers13164019

32. Carfilzomib, Cyclophosphamide, and Dexamethasone (KCd) for the Treatment of Triple-class Relapsed/Refractory Multiple Myeloma (RRMM): A Single Institution Experience Dante Pennipede, Ghulam Rehman Mohyuddin, Ryan Hawkins, Siddhartha Ganguly, Leyla Shune, Nausheen Ahmed, Meera Mohan, Wei Cui, Zahra Mahmoudjafari, Joseph McGuirk, Shebli Atrash, Al-Ola Abdallah Eur J Haematol. 2021 Aug 11. doi: 10.1111/ejh.13697

33. Infectious Complications with CD-38 Targeting Monoclonal Antibody Based Therapies in Multiple Myeloma: A Meta-analysis of Randomized Control Trials. Naveen Yarlagadda MD, MS; Sravani Gundarlapalli MD; Smriti Sharma MD; Elizabeth Suelzer; Muhammad Bilal Abid MD; Al-Ola Abdallah MD; Carolina Schinke MD, Shelbi Atrash MD, MS*; Meera Mohan MD, MS* Leukemia research Sep 2021 https://doi.org/10.1016/j.leukres.2021.106714

34. The Role of Monoclonal Antibodies in the Era of Bi-specifics antibodies and CAR-T cell therapy in Multiple Myeloma Meera Mohan MD, MS; Theresa Camille Maatman MD; Carolina Schinke MD Cancers 2021, 13(19), 4909; https://doi.org/10.3390/cancers13194909

35. Shorter Interval between Treatment and COVID Immunization is Associated with Poor Seroconversion in Patients with Hematological Malignancies Meera Mohan, Sneha Nagavally, Nirav N Shah N, Laura Michaelis, Saurabh Chhabra, Anita D’Souza, Sameem Abedin, Lyndsey Runaas, Guru Subramanian Guru Murthy, Walter Longo, Nathan Ledeboer, Mehdi Hamadani M, Binod Dhakal, Parameswaran Hari, Timothy S Fenske Submitted to Clinical Myeloma Lymphoma Leukemia (under review)

36. Risk of infections with BCMA-directed Immunotherapy in Multiple Myeloma Meera Mohan MD, MS; Sneha Nagavally; Binod Dhakal MD, MS; Sabarinath Venniyil Radhakrishnan MD; Saurabh Chhabra MD, MS; Anita D’Souza MD, MS; Parameswaran Hari MD Submitted to Blood Advances (In Press)

37. Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance Meera Mohan, MD, Naveen K Yarlagadda MD, Shebli Atrash, MD, Sravani Gundarlapalli, Shadiqul Hoque, MD, Sunil Kakadia, MD, Sharmilan Thanendrarajan, MD, Carolina Schinke, MD, Daisy Alapat, Guido Tricot, MD, PhD, Erming Tian, PhD, MBA, Jeffery R. Sawyer, Fenghuang Zhan, MD.Ph., Frits van Rhee, MD, Maurizio Zangari, MD, FACP

38. Addressing the disparities and the factors related to prolonged inpatient length of stay for solid tumor oncology patients during the COVID-19 pandemic: A narrative review Kamaraju S *, Mohan M, Wright T, Charlson J, Wiger W, Kwarteng J, Rezazadeh A , Hammons L and Power S Journal of Radiology and Oncology DOI: 10.29328/journal.jro.1001038

39. Black Patients with Multiple Myeloma Have Better Survival than White Patients When Treated Equally: A Matched Cohort Study Jing Dong, PhD1, Zhuping Garacci, PhD2*, Christopher Staffi Buradagunta, MS1*, Meera Mohan, MD1, Anita D'Souza, MD, MS3, Ashley Cunningham, MD4*, Siegfried Janz, MD, DSc1, Binod Dhakal, MBBS1 and Parameswaran Hari5 Submitted to Blood Cancer Journal

40. Gender Disparities in Multiple Myeloma Publications Aala Dweik MD, Hadeel Dweik MD, Hira Mian MD, Meera Mohan MD MS, Carolina Schinke MD, Samer Al Hadidi MD MS. eJHaem. 2022 Jun 17 doi.org/10.1002/jha2.470

41. Clinical Efficacy of Sequencing CD38 targeting monoclonal antibodies in Relapsed Refractory Multiple Myeloma: A multi-institutional real-world experience. Meera Mohan, MS; Melody Renee Becnel, Urvi A. Shah, Huaying Dong,Sravani Gundarlapalli, Tim Peterson, Jennifer S. Orozco, Sandra Horowitz, Lei Feng, Saurabh Chhabra, Binod Dhakal, Sharmilan Thanendrarajan, Sabarinath Venniyil Radhakrishnan, Samer Al Hadidi, Carlyn Tan, Sham Mailankody, Malin Hultcrantz, Neha Korde, Hani Hassoun, Alexander M. Lesokhin,Sheeba K. Thomas, Krina K. Patel, Elisabet E. Manasanch, Donna M. Weber, Aniko Szabo, Greg P. Kaufman, Hans C. Lee, Maurizio Zangari, Frits van Rhee, Saad Z. Usmani, Anita D’Souza, Robert Z. Orlowski, Carolina Schinke, Am J Hematol. 2022 Apr 26. doi: 10.1002/ajh.26580

42. Effectiveness of mRNA-based SARS-CoV-2 vaccine booster among non-seroconverting hematopoietic cell transplantation, CAR T-cell and BiTE recipients. Muhammad Bilal Abid, Micah Rubin, Nathan Ledeboer, Aniko Szabo, Walter Longo, Meera Mohan, Nirav Shah, Timothy Fenske, Sameem Abedin, Lyndsey Runaas, Anita D’Souza, Saurabh Chhabra, Binod Dhakal, Mehdi Hamadani. Cancer Cell. 2022 Feb 23:S1535-6108(22)00062-9

43. Neutralizing antibody responses against SARS-CoV-2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination, Al-Ola Abdallah , Zahra Mahmoudjafari , Tahani Atieh , Nausheen Ahmed, Wei Cui, Leyla Shune, Meera Mohan, Joseph McGuirk, Cassie Remker, Margaret Foss, Ellie Karloff, Heather Fitch, Shebli Atrash

44. Clinical efficacy of retreatment of daratumumab-based therapy (D2) in daratumumab-refractory multiple myeloma. Al-Ola Abdallah, Zahra Mahmoudjafari; Nausheen Ahmed; Wei Cui; Leyla Shune; Joseph McGuirk; Meera Mohan, Ghulam Rehman Mohyuddin; Aimaz Afrough; Omar Alkharabsheh; Shebli Atrash, Submitted Clinical Leukemia, Lymphoma and Myeloma (under review)

45. A Timeline of Genetic Variant Enrichment-From Multiple Myeloma Diagnosis to Myeloma-Associated Myeloid Malignancy Variant Evolution in Myeloma-Associated MDS/AML. Ariel Kleman, Arun Singavi, Lauren Pommert, Angela Matheson, Parameswaran Hari, Binod Dhakal, Meera Mohan, Siegfried Janz, Jennifer Knight, Mithun Shah, Caroline Schinke, Robert Burns, Sridhar Rao, Karen Carlson. Blood Adv. 2023 Feb 1;bloodadvances.2022008953. doi:10.1182/bloodadvances.2022008953

46. Corneal Toxicity Limits Clinical Efficacy of Belantamab mafodotin: Multi-institutional Real-Life Experience. Meera Mohan1, Lisa E Rein, Nishanth Thalambedu, Yetunde Ogunsesan, Munawwar Hussain, Jaskirat Sethi, Fatima Khan, Sravani Gundarlapalli, Lakshmi Yarlagadda, Binod Dhakal, Sharmilan Thanendrarajan, Siegfried Janz, Sabarinath Venniyil Radhakrishnan, Samer Al Hadidi, Aniko Szabo, Anita D’Souza, Maurizio Zangari, Frits van Rhee, Saurabh Chhabra, Carolina Schinke. American Journal of Hematology 2022 Sept doi:10.1002/ajh.26728

47. Incidence of second primary malignancies in patients with multiple myeloma receiving anti-CD38 monoclonal antibodies: a systematic review and meta-analysis. Agrima Mian, Syed Arsalan Ahmad Naqvi, Ahsan Ayaz, Muhammad Husnain, Mohammed A. Aljama, Ghulam Rehman Mohyuddin, Kelly Koehn, Meera Mohan, Irbaz Bin Riaz, Rajshekhar Chakraborty. Submitted to European Journal of Hematology.

48. Clinical Outcome of Patients with Relapsed Refractory Multiple Myeloma Listed for BCMA Directed Commercial CAR-T Therapy. Samer Hadidi MD MS, Aniko Szabo PhD, Jean Esselmann RN, Lindsay Hammons MD, Munawwar Hussain MD, Yetunde Ogunsesan MD, Nishanth Thalambedu MD, Fatima Khan MD, Jaskirat Sethi MD, Abhishek Janardhan, Sabarinath Venniyil Radhakrishnan MD, Sharmilan Thanendrarajan MD, Carolina Schinke MD, Binod Dhakal MD, Siegfried Janz MD DSc, Saurabh Chhabra MD, Anita D’Souza MD, Maurizio Zangari MD, Frits van Rhee MD PhD, Meera Mohan MD MS. Bone Marrow Transplant 2022 Dec 22. doi: 10.1038/s41409-022-01905-1

49. Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd alone for patients with Relapsed Refractory Multiple Myeloma, Hamza Hashmi1, Atrash Shebli, Jayanshu Jain, Ghena Khasawneh, Meera Mohan, Zahra Mahmoudjafari, Wei Cu, Joseph McGuirk, Leyla Shune, Nausheen, Ahmed, Al-Ola Abdallah. Bone Marrow Transplantation, Jan 2023, doi.org/10.1016/j.jtct.2023.01.013

50. Change in cytokine levels at one-year after autologous hematopoietic cell transplantation in multiple myeloma patients on maintenance lenalidomide therapy: a correlative subset analysis of BMT CTN 0702. Meera Mohan, Siegfried Janz, Ruta Brazauskas, Michael B. Dwinell, Bi Qing Teng, Grant Yun, Jing Dong, Marcelo C. Pasquini, Sergio Giralt, Heather Landau, Edward Stadtmauer, Amrita Krishnan, Kathryn E. Flynn, Anita D’Souza. Submitted to Bone Marrow Transplantation

51. Recommendations on Prevention of Infections in Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapy in Multiple Myeloma. Meera Mohan1; Rajshekhar Chakraborty2; Susan Bal3; Muhamed Baljevic4, Anita D’Souza1, Jesus G. Berdeja5, Natalie Callander6, Luciano J. Costa3. Submitted to Leukemia

52. Blood and Marrow Transplant Within Four Weeks of SARS-CoV-2 Infection Is Associated with Increased Risk of Mortality: A National COVID Cohort Collaborative Study. Meera Mohan, Anai Kothari, Nathaniel Verhagen, Adithya Shreenivas, Sabarinath Venniyil Radhakrishnan, Binod Dhakal, Carlos Figueroa-Castro, Saurabh Chhabra, Siegfried Janz, Marcello Pasquini, Mehdi Hamadani, Aniko Szabo, Anita D’Souza. Submitted to Journal of Clinical Oncology

53. Chimeric antigen receptor and bispecific engager T-cell therapies in multiple myeloma patients with prior allogeneic transplantation. Lindsay Hammons, Anthony Zamora, Shabi Haider, Anthony Portuguese, Rahul Banerjee, Aniko Szabo, Marcelo Pasquini, Saurabh Chhabra, Sabarinath Radhakrishnan, Meera Mohan, Ravi Narra, Jing Dong, Siegfried Janz, Nirav Shah, Mehdi Hamadani, Anita D’Souza, Parameswaran Hari, Binod Dhakal

54. Changing Spectrum of Infection with BCMA and GPRC5D Targeting Bispecific Antibody Therapy in Patients with Relapsed Refractory Multiple Myeloma. Authors: Lindsay Hammons MD, Aniko Szabo Ph.D., Abhishek Janardan BA, Vineel Bhatlapenumarthi MD, Evanka Annyapu BS, Binod Dhakal MD, MS; Samer Hadidi MD, MS; Sabarinath Venniyil Radhakrishnan MD; Ravi Narra MD,Divaya Bhutani MD; Sharmilan Thanendrarajan MD; Siegfried Janz MD DSc; Maurizio Zangari MD; Suzanne Lentzsch MD Ph.D.; Frits van Rhee MD Ph.D.; Anita D’Souza MD, MS; Rajshekhar Chakraborty MD, Carolina Schinke MD; Meera Mohan MD, MS.Submitted to British Journal of Hematology

55. Sustained Disease Remission Following a Finite Duration of Bispecific Antibody Therapy in Patients with Relapsed Refractory Multiple Myeloma: A Case Series. Anannya Patwari, Heloise Cheruvalath, Divaya Bhutani, Carolina Schinke, Suzanne Lentzsch, Anita D’Souza, Rajshekhar Chakraborty MD, Meera Mohan. Submitted to Blood Advances

56. Phase 1b study of the anti-CD38 antibody mezagitamab in patients with relapsed/refractory multiple myeloma. Amrita Y. Krishnan,1 Krina K. Patel,2 Meera Mohan,3 Sundar Jagannath,4 Ruben Niesvizky,5 Rebecca W. Silbermann,6 Ziji Yu,7 Liwen Wu,7 Tao Long,7 Scott RP McDonnell,7 Deborah Berg,7 Keith E. Stockerl-Goldstein8. Submitted to Blood Advances.

57. Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study. Meera Mohan MD1; Jorge Monge MD2; Nishi Shah MD3; Danny Luan MD2; Mark Forsberg MD3, Vineel Bhatlapenumarthi MD1, Metodi Balev MD4; Anannya Patwari MD1; Heloise Cheruvalath BS5; Divaya Bhutani MD4 ; Sharmilan Thanendrarajan MD6; Binod Dhakal MD1; Maurizio Zangari MD6; Samer Al-Hadidi MD6, Dennis Cooper MD3; Suzanne Lentzsch MD4; Frits van Rhee MD7; Anita D’Souza MD1; Aniko Szabo Ph.D7; Carolina Schinke MD6; Rajshekhar Chakraborty MD4. Blood Cancer Journal volume 14, Article number: 35 (2024)

58. The Effect of Stem Cell Infusion on Immune Effector Cell Associated Hematotoxicity with BCMA CAR T Cell Therapy in Multiple Myeloma. Meera Mohan MD, MS 1; Aniko Szabo Ph.D. 3 ; Anannya Patwari MD 1; Jean Esselmann RN 1 ;Tanvi Patel, MD 2; Ramya Bachu, MD 2; Lisa E Rein ScM 3 ; Abhishek Janardan BA 4; Vineel Bhatlapenumarthi MD 1; Evanka Annyapu BS 4; Catherine Skoog PA 1; Areyl Goff APRN 1; Samer Al Hadidi MD MS 2; Sabarinath Venniyil Radhakrishnan MD 1; Sharmilan Thanendrarajan MD 2; Maurizio Zangari MD 2 ; Nirav Shah MD 1; Frits van Rhee MD Ph.D. 2; Binod Dhakal MD, MS 1; Medhi Hamadani MD 1 ; Anita D’Souza MD, MS 1; Carolina Schinke MD 2. Bone Marrow Transplant.2024 Feb 15. doi: 10.1038/s41409-024-02233-2

59. Adverse Effects and Non-Relapse Mortality of BCMA directed T cell Therapies in Multiple Myeloma: An FAERS Database Study. Zimu Gong MD, Ph. D.1; Godsfavour Umoru, PharmD1; Jorge Monge MD2; Nishi Shah MD3; Ghulam Rehman Mohyuddin MD4; Sabarinath Venniyil Radhakrishnan MD5; Rajshekhar Chakraborty MD6; Leo Rasche MD7; Carolina Schinke MD8; Anita D’Souza MD5; Meera Mohan MD5. Blood Cancer Journal volume 14, Article number: 36 (2024)

60. Current Status on Management of Primary Plasma Cell Leukemia Zimu Gong MD1, Meera Khosla MD2, Sreeraj Vasudevan MD3, Meera Mohan MD4. Submitted to Current Oncology Reports (under review)

61. The impact of socioeconomic factors on systemic light chain (AL) amyloidosis outcomes. Mingqian Lin, MS, Aniko Szabo, PhD, Liliana Pezzin, PhD, JD, Jing Dong, PhD, Binod Dhakal, MD, MS, Meera Mohan, MD, MS, FACP, Ravi Narra, MD, MS, Marcelo Pasquini, MD, Anita D’Souza, MD, MS. Submitted to Health Equity (under review)

62. Outpatient Administration of Step Doses of Teclistamab: A Single-Institution Experience. Meera Mohan MD1; Ravi Narra MD1; Aniko Szabo Ph.D.2; Vineel Bhatlapenumarthi MD1; Anannya Patwari MD1; Heloise Cheruvalath BS3; Emilie Aschenbrenner PharmD1; Catherine Skoog PA1; Areyl Goff APRN1; Othman Salim Akhtar MD1; Binod Dhakal MD1; Mehdi Hamadani MD1; Anita D’Souza MD1. Submitted to European Journal of Hematology (under review).

63. Risk Stratification in Multiple Myeloma: Are we there yet? Meera Mohan MD, Carolina Schinke MD. Accepted to British Journal of Hematology

64. Timing of Toxicities and Non-relapse Mortality Following CAR T Therapy in Myeloma William Wesson, Danai Dima, Nahid Suleman1, Md Saiful Islam Saif, Carine Tabak,nEmerson Logan, James A. Davis, Mary McGann, Fateeha Furqan, Meera Mohan, Aliya Rashid, Al–Ola Abdallah, Leyla Shune, Muhammad Umair Mushtaq, Shahzad Raza, Joseph McGuirk, Mehdi Hamadani, Faiz Anwer, Hamza Hashmi, Nausheen Ahmed. Submitted to British Journal of Hematology (under review)

1. Principles of Drug Metabolism and Interactions in Cardio-Oncology Drug Metabolism Handbook: Concepts and Applications in Cancer Research 2nd Edition (In Press) Sherry-Ann Brown MD PhD, Craig Beavers PharmD, Sailaja Kamaraju MD, Meera Mohan MD, Olubadewa Fatunde MD MPH, Gift Echefu, MD, Svetlana Zaharova1, Brianna Wallace, Carolyn Oxencis PharmD

2. Immunotherapy - Chimeric Antigen Receptor –T cell and Bispecific T Cell Engager in Multiple Myeloma Expert Clinical Perspective: Controversies and Uncertainties in Diagnosis & Management of Cancer, 2nd Edition Meera Mohan, Parameswaran Hari, Saurabh Chhabra

3. Updates in the Management of Multiple Myeloma from the American Society of Hematology Meeting 2021. Sreeraj Vasudevan MD, DM, Sravani Gundarlapalli MD, Nishanth Thalambedu MD, Meera Mohan MD, MS, FACP. touchREVIEWS in Oncology & Haematology. 2022;18(1)

1. My Strangest Case: The Man with a Heavy Tongue. Meera Mohan MD, MS, Paulette Mehta MD. Medscape - Aug 04, 2020.

2. Understanding the Stages of Multiple Myeloma: Q&A With Dr. Mohan | MyMyelomaTeam

1. Comparison of endoscopist administered conscious sedation versus anesthesiologist Administered deep sedation for gastrointestinal endoscopy in an ambulatory surgery center. What should be the standard of care? Advani, Vriti; Wietfeldt, Elizabeth D; Mohan, Meera; Siddagunta, Chaitanya; Boehler, Margaret; Hassan, Tariq; Hassan, Imran. Poster presented at: Digestive disease week 2011; New Orleans, LA.

2. Suboptimal Implementation of Diagnostic Algorithms and Overuse Of CT-Pulmonary Angiography In Patients With Suspected Pulmonary Embolism: A Retrospective Study S. Alhassan, A. Abu-sayf, C. Arsene, M. Mohan, B. Fraser, M. Ghiarai, T. Kuhta, H. Krayem. Poster presented at: American thoracic Society Meeting; Philadelphia, PA (2013).

3. Defining the Impact of Tandem Autologous Stem Cell Transplantation in Multiple Myeloma: A Case-Match Analysis in the Total Therapy Trials. Sharmilan Thanendrarajan, Caleb K. Stein, Faith E Davies, Frits van Rhee, Maurizio Zangari, Christoph Heuck, Carolina Schinke, Sarah Waheed, Yogesh Jethava, Niels Weinhold, Aasiya Matin, Pankaj Mathur, Meera Mohan, Muthukumar Radhakrishnan, Bart Barlogie. Poster presented at: American Society of Hematology; Orlando, FL (2015).

4. Impact of Minimal Residual Disease in High and Standard Risk Multiple Myeloma. Carolina Schinke, Shayu Deshpande, Alan Mitchell, Malek Faham, Purvi Patel, Sharmilan Thanendrarajan, Meera Mohan, Pankaj Mathur, Aasiya Matin, Muthukumar Radhakrishnan, Ruslana Tytarenko, Owen W Stephens, Frits van Rhee, Maurizio Zangari, Yogesh Jethava. Poster presented at: American Society of Hematology; Orlando, FL (2015).

5. Clinical and Molecular Characterization of Primary Plasma Cell Leukemia Sandra Susanibar, Pingping Qu, Antje Hoering, Sharmilan Thanendrarajan, Jorge Jo Kamimoto, Meera Mohan, Pankaj Mathur, Shadiqul Hoque, Muthukumar Radhakrishnan, Frits van Rhee, Maurizio Zangari, Faith E. Davies, Daisy Alapat, Barlogie Bart, Gareth J. Morgan and Carolina D. Schinke. Poster presented at: American Society of Hematology Meeting; Orlando, FL (2015).

6. Comprehensive Genomic Profiling of Multiple Myeloma during Clinical Care Identifies Targetable and Prognostically Significant Genomic Alterations. Christoph Heuck, Shweta S. Chavan, Caleb K. Stein, Ruslana Tytarenko, Niels Weinhold, Siraj Ali, Vincent A. Miller, Sharmilan Thanendrarajan, Carolina Schinke, Meera Mohan, Jeffery Sawyer, Erich Allen Peterson, Michael Bauer. Poster presented at: American Society of Hematology Meeting; Orlando, FL (2015).

7. Re-Mineralization of Large Pelvic Lytic Lesions by CT Imaging in Patients with Multiple Myeloma: The Arkansas Experience. Meera Mohan, Rohan Samant, Larry J Suva, Corey O Montgomery, Daisy V. Alapat, Roy Morello, Frits van Rhee, Sarah Waheed, Sharmilan Thanendrarajan, Carolina Schinke, Christoph Heuck, Yogesh Jethava, Donald Johann, Bart Barlogie, Faith E Davies, Gareth. Poster presented at: American Society of Hematology; Orlando, FL (2015).

8. Bacteremias Following Autologous Stem Cell Transplantation for Hematologic Malignancies and Solid Tumors: Risk Factors and Outcomes. Kothari A, Susanibar-Adaniya SP, Mohan M, Saylors ME, Lusardi KT, Rico Crescencio JC, Burgess MJ, Bariola JR. Poster presented at: American Society of Microbiology meeting; Boston, MA (2016).

9. The Expression of PTH1 and PTH2 Receptors in Bone Marrow is Associated with the Progression of Newly Diagnosed Myeloma Patients Maurizio Zangari, Amy Buros, Donghoon Yoon, Antonio Branca, Carolina Schinke, Sharmilan Thanendrarajan1, Larry J. Suva, Meera Mohan, Faith Davies, Frits van Rhee, Gareth Morgan. Poster presented at: American Society of Bone and Mineral Research; Atlanta, GA (2016).

10. Next Generation Sequencing (NGS) based Minimal Residual Disease (MRD) testing is highly predictive of Overall and Progression Free Survival in the Total Therapy Trials and shows different prognostic implications in High vs Standard Risk Multiple Myeloma. Carolina Schinke, Shayu Deshpande, Hongwei Wang, Victoria Carlton, Katherine Kong, Martin Moorhead, Tom Willis, Purvi Patel, Sharmilan Thanendrarajan, Meera Mohan, Pankaj Mathur, Sandra Susanibar, Shadiqul Hoque, Muthukumar Radhakrishnan, Ruslana Tytarenko, Owen Stephens, Leo Rasche, Frits van Rhee, Mauricio Zangari, Nathan Petty, Daisy Alapat, Sarah Johnson, Josh Epstein, Bart Barlogie, Faith Davies, Antje Hoering, Niels Weinhold, Gareth Morgan. Poster presented at: American Society of Hematology; San Diego (2016).

11. Parathyroid Hormone Receptor 1 & 2 gene expression from bone marrow biopsy modulates plasma cell GEP derived myeloma survival. Maurizio Zangari, Amy Buros, Donghoon Yoon, Larry J. Suva, Antonio Branca, Niels Weinhold, Leo Rasche, Carolina Schinke, Sharmila Thanendrarajan, Meera Mohan, Faith Davies, Frits van Rhee, Gareth Morgan. Poster presented at: American Society of Hematology; San Diego (2016).

12. Daratumamab in High-Risk Relapse/Refractory Myeloma Patients. Effect of 1q21 Duplication and GEP70 Status. Meera Mohan, Frits van Rhee, Sharmilan Thanendrarajan, Carolina Schinke, Faith E Davies, Gareth Morgan, Maurizio Zangari. Poster presented at American Society of Hematology meeting 2017.

13. Effect of Bone allograft in multiple myeloma spine surgeries. Mohan M, Samant R, Buros A, Alapat D,Walter J, Pait T, Gahleb N, Thanendrarajan S, van Rhee F, Davies F, Morgan G, Schinke C ,Suva LJ ,Zangari M. Poster presented at ASMBR Conference in Denver, CO (2017)

14. Respiratory Viral Infections in Multiple Myeloma Patients. Mohan M, Kothari A, Susanibar-Adaniya SP, Saylors ME, Lusardi KT, Rico Crescencio JC, Burgess MJ. Poster presented at ID week, San Diego, CA (2017).

15. Refilling of Bony Myeloma Lytic lesion in patients treated on Total Therapy 4 protocol. Maurizio Zangari, Niels Weinhold, Larry Suva, Meera Mohan, Donghoon Yoon, Faith Davies, Gareth Morgan, Frits van Rhee, Sharmilian Thanendararjan, Carolina Schinke, Manoj Kumar. Presented at the Molecular Pharmacology and Therapeutics of Bone and other Musculoskeletal Diseases and Cancer and Bone Society 2018 Meeting, Oxford UK, June 2018.

16. Remineralization of Bone Lytic Lesions in high-risk myeloma patients enrolled on total therapy five protocol (TT5); the Arkansas experience. Maurizio Zangari, Shivang Desai, Meera Mohan, Frits van Rhee, Sharmilan Thanendrarajan, Carolina Schinke, Faith Davies, Gareth Morgan, Larry J. Suva, Donghoon Yoon, Leo Rasche, Niels Weinhold, Shobhit Sharma, Manoj Kumar. Presented as poster at ASMBR Conference, Denver, and August 2018.

17. Severity and outcomes of Toxin negative vs Toxin positive patients with Clostridium Difficile infection Jorge Jo Kamimoto MD; Sandra Susanibar Adaniya MD; Meera Mohan MD; Piroon Jenjaroenpun PHD; Gayathri Krishnan MD; Juan CR Crescencio MD; Mary J Burgess MD; Ruslana Tytarenko MS, Nicole Emery M(ASCP); Eric R Rosenbaum MD, PHD; Brain Walker PHD; Intawat Nookaew PHD; Atul Kothari MD. Presented at ID week, San Diego September 2018.

18. The Mutational Landscape of Primary Plasma Cell Leukemia Carolina Schinke, Cody Ashby, Yan Wang, Ruslana Tytarenko, Eileen Boyle, Christopher Wardell, Pingping Qu, Sharmilan Thanendrarajan, Sandra Susanibar, Naveen Yarlagadda, Maliha Khan, Meera Mohan, Maurizio Zangari, Frits van Rhee, Faith Davies, Bart Barlogie, Gareth Morgan, Brian Walker Oral abstract presented at American Society of Hematology meeting, San Diego, Dec 2018

19. Survey of Compliance to Infection Control Measures and Its Impact on Healthcare of Patients in a Hematopoietic Stem Cell Transplant Unit Naveen Yarlagadda, Gayatri Krishnan, Meera Mohan, Andrew Johnsrud, Frankie Wolfe and Atul Kothari Blood 2018 132:582. Published online in blood.

20. Treatment of Unresectable Unicentric Castleman Disease with Therapeutic Embolization Meera Mohan, James C Meek, Mary Elizabeth Meek, Ralph Broadwater, Katie Stone, Amy Greenway, Daisy Alapat, Frits van Rhee. Poster Abstract presented at American Society of Hematology meeting, San Diego, Dec 2018.

21. Genomic surveillance for nosocomial outbreak with vancomycin-resistant Enterococcus faecium strains from cancer patients with bacteremia and urinary tract infections Zulema Udaondo, Thidathip Wongsurawat, Piroon Jenjaroenpun, Kaleb Abram, Courtney Anderson, James Lopez, Meera Mohan, Ruslana Tytarenko, Brain Walker, David Ussery, Atul Kothari, * Se-Ran Jun Human Genome Meeting “Towards Implementing Genomic Medicine”, Seoul, Korea, Apr 24-26, 2019. (The best poster award for achievement of excellent presentation)

22. Familial pregnancy-associated aHUS and acute heart failure A.Java, Z Ren, M Mohan, A Sasapu, P Motwani, J Atkinson Presented as Poster at American Society of Nephrology (ASN) conference 2019

23. Study of bloodstream co-infection by Vancomycin Resistant Enterococcus strains in an inpatient with Acute Lymphocytic Leukemia using Oxford Nanopore and Illumina sequencing Zulema Udaondo, Piroon Jenjaroenpun, Thidathip Wongsurawat , Brian Walker , Courtney Anderson , James Lopez , Meera Mohan , Noor ul Hudda , David Ussery , Atul Kothari , Se-Ran Jun. Presented as Poster Abstract at the Oxford Nanopore meeting, NY 2019.

24. Whole-Genome Analysis of VREfm Isolates with Daptomycin Resistance Using Oxford Nanopore and Illumina Sequencing Piroon Jenjaroenpun, Zulema Udaondo, Thidathip Wongsurawat, Kaleb Abram,CourtneyAnderson, James Lopez, Meera Mohan , Ruslana Tytarenko, Brian Walker, David Ussery, Se- Ran Jun, Atul Kothari. Presented as poster at the American Society of Microbiology meeting 2019, June 20-24,2019, San Francisco, CA

25. Study of bloodstream co-infection by vancomycin resistant Enterococcus strains in an inpatient with Acute Lymphocytic Leukemia using Nanopore and Illumina sequencing. Udaondo Z, Jenjaroenpun P, Wongsurawat T, Walker B, Anderson C, Lopez J, Mohan M, Hudda N, Ussery D, Kothari A, Jun SR. Nanopore Community Meeting, New York City, Dec 5 - Dec 6, 2019. (Highly commended award)

26. Clinical Implications of Loss of Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Meera Mohan, Naveen Yarlagadda, Dinesh Atwal, Yadav Pandey, Arya Roy, Richa Parikh, James Lopez, Sharmilan Thanendrarajan, Carolina Schinke, Daisy Alapat, Frits van Rhee, Samantha Kendrick, Maurizio Zangari Poster discussion session American society of clinical oncology 2020 meeting (poster discussion session highlights the selected 12 posters in the plasma cell dyscrasia to be discussed by a panel of 4 experts in the field). This was chosen as one of the top abstracts from ASCO 2020 meeting by the International Myeloma Foundation and simultaneously featured on their official website.

27. Feasibility of outpatient stem cell transplantation in multiple myeloma and risk factors that predispose for hospital admission. Kristin Larsen, Meera Mohan, Clyde Bailey, Kerri Hill, Horace Spencer, Mathew Kottarathara, Richa Parikh, Shadiqul Hoque, Erra Amani, Angel Mitma, Pankaj Mathur, Guido Tricot, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee and Carolina Schinke Presented at American Society of Hematology meeting 2020.

28. Late Relapsing Multiple Myeloma ≥ 10 years after Treatment on Total Therapy Protocols Meera Mohan MD MS, Samantha Kendrick PhD,Yadav Pandey MD, Richa Parikh MD, Phillip Farmer ,Mathew Kottarathara MD, Shadiqul Hoque MD, Angel Mitma MD,Sharmilan Thanendrarajan MD, Carolina Schinke MD, Guido Tricot MD PhD, Maurizio Zangari MD Frits van Rhee MD PhD. Presented at American Society of Hematology meeting 2020.

29. The role of Salvage Autologous Stem Cell Transplantation in Penta-refractory Multiple Myeloma Lakshmi Yarlagadda, Sravani Gunarlapalli, Richa Parikh, Mathew Kottarathara, Yetunde Ogunsesan, Shadiqul Hoque, Angel Mitma, Clyde Bailey, Kerri Hill, Sharmilan Thanendrarajan, Monica Graziutti, Meera Mohan, Maurizio Zangari, Frits van Rhee Guido Tricot, and Carolina Schinke Presented at American Society of Clinical Oncology 2021 Meeting (online publication)

30. Phase 1b/2 Study of the First-in-class SUMO-activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-class Refractory Multiple Myeloma Sagar Lonial, Stefano Tarantolo, Ralph Boccia, Habte A. Yimer,Moshe Yair Levy, Rafat Abonour, Meera Mohan, Vivek Roy,Jeremy T. Larsen, Saulius Girnius, Cara Rosenbaum, Omar Nadeem, Deborah Berg,Bo Chao, Allison J. Berger, Akito Nakamura, Yuhong Zhang,Keli Song, Christine Ward,Igor Proscurshim, Shaji K. Kumar Presented as Poster at the American Society of Hematology Meeting 2021 (Dec 11-14, 2021)

31. Phase 2 trial of polyclonal Temsirolimus- resistant autologous Th1/Tc1 cells (RAPA 201) for Relapsed Refractory Multiple Myeloma Binod Dhakal, Tania Felizardo, Anita D’Souza, Saurabh Chhabra, Taylor Keaton, Meera Mohan, Hyun Park, Daniel H. Fowler, and Parameswaran Hari. Presented as Poster at the American Society of Hematology Meeting 2021 (Dec 11-14, 2021)

32. Belantamab in combination with dexamethasone in patients with triple-class Relapsed/Refractory RRMM in the real world.Tahani Atieh, Shebli Atrash, Nausheen Ahmed, Meera Mohan, Wei Cui, Leyla Shune, Zahra Mahmoudjafari, Julie Quick, Anne Wishna, Justin Riffel, Joseph McGuirk, Ghulam Rehman Mohyuddin, Al-Ola Abdallah. Presented as Poster at the American Society of Hematology Meeting 2021 (Dec 11-14, 2021)

33. Clinical efficacy of re-treatment of daratumumab-based therapy in relapsed/refractory multiple myeloma who are daratumumab refractory Al-Ola Abdallah, Zahra Mahmoudjafari, Nausheen Ahmed, Meera Mohan, Wei Cui, Leyla Shune, Joseph McGuirk, Ghulam Rehman Mohyuddin, Shebli Atrash Presented as Poster at the American Society of Hematology Meeting 2021 (Dec 11-14, 2021)

34. Neutralizing antibody responses against SARS-CoV-2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination Al-Ola Abdallah, Zahra Mahmoudjafari, Meera Mohan, Joseph McGuirk, Cassie Remker, Margaret Foss, Ellie Karloff, Heather Fitch, Ghulam Rehman Mohyuddin, Shebli Atrash Presented as Poster at the American Society of Hematology Meeting 2021 (Dec 11-14, 2021)

35. Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma (RRMM): Is there an excess risk of infection? Meera Mohan MD, MS; Sneha Nagavally; Binod Dhakal MD, MS; Anita D’Souza MD, MS; Saurabh Chhabra MD, MS; Parameswaran Hari MD, MS. Presented as Poster at the American Society of Hematology Meeting 2021 (Dec 11-14, 2021)

36. Eight Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance Naveen Yarlagadda MD, MS*, Meera Mohan MD MS*, Shebli Atrash MD MS, Sravani Gundarlapalli MD, Shadiqul Hoque, MD Sunil Kakadia MD, Sharmilan Thanendrarajan MD, Carolina Schinke MD, Daisy Alapat MD, Jeffery Sawyer PhD, Erming Tian PhD, Guido Tricot MD, Fenghuang Zhan MD PhD, Frits van Rhee MD PhD, Maurizio Zangari MD Presented as Poster at the American Society of Hematology Meeting 2021 (Dec 11-14, 2021)

37. Concomitant deletion of short arm (del 1p) and amplification or gain (1q21) of chromosome 1 by Interphase fluorescence in situ hybridization (iFISH) is associated with poor clinical outcome Meera Mohan MD, Zimu Gong MD PhD, Samantha Kendrick PhD, Sharmilan Thanendrarajan MD, Carolina Schinke MD, Daisy Alapat MD, Guido Tricot MD, Fenghuang Zhan MD PhD, Frits van Rhee MD PhD, Jeffrey Sawyer PhD, Erming Tian PhD, Maurizio Zangari MD Presented as Poster at the American Society of Hematology Meeting 2021 (Dec 11-14, 2021)

38. Characteristics Associated with Disparities in Survival between Hispanic and Non-Hispanic White Patients with Multiple Myeloma: A Matched Cohort Study. Jing Dong, PhD, Zhuping Garacci, PhD, Christopher Staffi Buradagunta, MS, Meera Mohan, MD, Anita D'Souza, MD, MS, Ashley Cunningham, MD, Siegfried Janz, MD, DSc, Binod Dhakal, MBBS and Parameswaran Hari Presented as Poster at the American Society of Hematology Meeting 2021 (Dec 11-14, 2021)

39. Impact of Autologous Hematopoietic Cell Transplant (HCT) Followed by Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance in Increasing Multiple Myeloma (MM) Immunity (BMT CTN 1401) David J. Chung, MD, PhD, Nina Shah, MD, Dina Stroopinsky, Juan WU, Lina Bisharat, Natalie S. Callander, MD, Brent R. Logan, PhD, Kenneth C. Anderson, MD, Thinle Chodon, MD, Meera Mohan, MD, Steven Devine, MD, Yvonne A. Efebera, MD, MPH, Nancy Geller, PhD, Peiman Hematti, MD, Leona A. Holmberg, MD, PhD, Alan Howard, PhD, Bryon Johnson, PhD, Hillard M Lazarus, MD, Ehsan Malek, MD, Philip L. McCarthy, MD, David H. McKenna, MD, Adam M. Mendizabal, MS, Nikhil C. Munshi, MD, PhD, Lynn O'Donnell, PhD, Aaron P. Rapoport, MD, Ajay K. Nooka, Jane Reese, Robert J. Soiffer, MD , Lynne Uhl, MD, Giulia Cheloni, PhD, Dimitra Karagkouni, PhD, Ioannis Vlachos, PhD, James W. Young, MD, Jacalyn Rosenblatt, MD, Edmund K. Waller, PhD, MD, Marcelo C Pasquini, MD, MS and David Avigan, MD Presented as oral presentation at the American Society of Hematology Meeting 2021 (Dec 11-14, 2021)

40. Exploring Interest in and Feasibility of a Lifestyle Intervention for Multiple Myeloma Patients Abigail Kerschner, Allen Hodge, Alexis Williams, MD, Patrica Sheean, PhD, Kathleen Jensik, Alexis Visotcky, MS, Parameswaran Hari, Meera Mohan, MD, Saurabh Chhabra, MD, MS, Anita D'Souza, MD, MS and Melinda Stolley, PhD Presented as Poster at the American Society of Hematology Meeting 2021 (Dec 11-14, 2021)

41. Tandem Autologous Stem Cell Transplantation in Patients with Persistent Bone Marrow Minimal Residual Disease Post First Transplantation in Multiple Myeloma. Meera Mohan, Sravani Gundarlapalli, Aniko Szabo, Naveen Yarlagadda, Yetunde Ogunsesan, Lakshmi Yarlagadda, Nishant Thalambedu, Hussain Munawar, Monica Graziutti, Sharmilan Thanendrarajan, Samer Al Hadidi, Maurizio Zangari, Frits van Rhee and Carolina Schinke Submitted to Tandem Meeting 2022

42. Kinetics of Humoral Immunodeficiency with Bispecific Antibody Therapy in Multiple Myeloma Lindsay R Hammons MD, Aniko Szabo PhD, Binod Dhakal MD, MS; Sabarinath Venniyil Radhakrishnan MD; Saurabh Chhabra MD, MS; Anita D’Souza MD, MS; Meera Mohan MD, MS. Poster Abstract ASCO Meeting 2022. Dr Hammons was awarded ASCO 2022 Conquer Cancer Merit Award

43. Risk of Adverse Postoperative Events in Patients Recovered from SARS-CoV-2 Infection Undergoing Pancreas Resection for Cancer: An N3C Study NB Verhagen, S Thalji, M Mohan, A Shreenivas, CN Clarke, KK Christians, S Tsai, DB Evans, A Szabo, AN Kothari. Poster abstract at the SAAS (Society of Asian Academic Surgeons) Annual meeting 2022.

44. UNIVERSAL Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma. Mailankody S, Matous JV, Liedtke M, Sidana S, Oluwole OO, Meera, M, Cruz JC, Nath R, Anwer F, Rossi, A, Htut M, Malik SA, Ghatta S, Dillon M, Ying W, Navale L, Karski EE, Balakumaran A, Kumar SK. Poster Abstract at American Society of Hematology, 2022

45. Daratumumab, pomalidomide and dexamethasone (DPd) versus Daratumumab, velcade and dexamethasone (DVd) in previously treated daratumumab naïve relapsed refractory Multiple Myeloma patients Evguenia Ouchveridze, Chandandeep Singh, Atrash Shebli, Barry Paul Meera Mohan, Omar Alkharabsheh, Aimaz Afrough, Wei Cui, Zahra Mahmoudjafari1, Al-Ola Abdallah, Hamza Hashmi. Poster Abstract at American Society of Hematology Meeting, 2022

46. Outcomes of patients with Relapsed/Refractory Multiple Myeloma (RRMM) who responded to Daratumumab, Pomalidomide and dexamethasone (DPd), followed by High dose chemotherapy/Autologous Stem Cell Transplantation (HDCT/ASCT) versus DPd alone . Jayanshu Jain , Ghena Khasawneh, Hamza Hashmi, Meera Mohan, Zahra Mahmoudjafari, Wei Cu, Jospeh McGuirk, Leyla Shune, Nausheen, Ahmed, Al-Ola Abdallah, Atrash Shebli. Poster Abstract at American Society of Hematology Meeting, 2022

47. Current wait time for patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR T therapy. Samer Hadidi MD MS, Aniko Szabo PhD2, Jean Esselmann RN2, Lindsay Hammons MD2, Munawwar Hussain MD1, Yetunde Ogunsesan MD1, Nishanth Thalambedu MD, Fatima Khan MD, Jaskirat Sethi MD, Abhishek Janardhan, Sabarinath Venniyil Radhakrishnan MD, Sharmilan Thanendrarajan MD, Carolina Schinke MD, Binod Dhakal MD, Siegfried Janz MD, PhD, Saurabh Chhabra MD, Anita D’Souza MD, Maurizio Zangari MD, Frits van Rhee MD PhD, Meera Mohan MD MS. Poster Abstract at American Society of Hematology Meeting, 2022.

48. Chimeric antigen receptor-T (CAR-T) cell therapy targeting BCMA in patients with prior allogeneic transplantation (allo-HCT) in relapsed and/or refractory multiple myeloma (RRMM). Lindsay Hammons, Shabi Haider, Marcelo Pasquini, Saurabh Chhabra, Sabarinath Venniyil Radhakrishnan, Anthony Zamora, Meera Mohan, Jing Dong, Siegfried Janz, Anita D’Souza, Parameswaran Hari, Binod Dhakal. Poster Abstract at American Society of Hematology Meeting, 2022.

49. Blood and Marrow Transplant Within Four Weeks of SARS-CoV-2 Infection Is Associated with Increased Risk of Mortality: A National COVID Cohort Collaborative Study. Meera Mohan, Nathaniel Verhagen, Adithya Shreenivas, Sabarinath Venniyil Radhakrishnan, Binod Dhakal, Saurabh Chhabra, Michael Thompson, Marcello Pasquini, Anita D’Souza, Mehdi Hamadani, Aniko Szabo, Anai Kothari. Oral Abstract at American Society of Hematology Meeting, 2022. Selected as one of the Transplantation presentations at the 2023 Highlights of ASH

50. Changing Spectrum of Infection with BCMA and GPRC5D Targeting Bispecific Antibody Therapy in Patients with Relapsed Refractory Multiple Myeloma(RRMM). Authors: Abhishek Janardan, Lindsay Hammons MD, Aniko Szabo Ph.D., Vineel Bhatlapenumarthi MD, Evanka Annyapu, Binod Dhakal MD, MS; Ravi Narra MD; Samer Hadidi MD, MS; Sabarinath Venniyil Radhakrishnan MD; Divaya Bhutani MD; Sharmilan Thanendrarajan MD; Siegfried Janz MD DSc; Maurizio Zangari MD; Suzanne Lentzsch MD Ph.D.; Frits van Rhee MD Ph.D.; Anita D’Souza MD, MS; Rajshekhar Chakraborty MD, Carolina Schinke MD; Meera Mohan MD, MS.

51. Dual targeting of SLAMF-7 and CD38 in Mulitple Myeloma (MM): A phase II study of Isatuximab, Elotuzumab, Pomalidomide and Dexamethasone (Isa-EloPD) in Relapsed and/or Refractory MM (RRMM) Binod Dhakal, Meera Mohan, Ravi Narra, Katie Palen, Aniko Szabo, Tyce Kearl, Ravi Gayathri, Susan Bal, Bryon Johnson, Marcelo Pasquini, Anita D’Souza, Luciano Costa. Poster Abstract at American Society of Hematology Meeting 2023 (December 9-12, 2023)

52. Gain1q in Myeloma Randomized Clinical Trials- How is it reported and how does it impact outcomes: A Systematic Review Karun Neupane, Gliceida Galarza Fortuna, Riyasha Dahal, Timothy Schmidt, Rafael Fonseca, Douglas Sborov, Meera Mohan, Hira Mian, Rajshekhar Chakraborty, Ghulam Rehman Mohyuddin. Poster abstract American Society of Hematology Meeting 2023 (December 9-12, 2023)

53. Initial Results From a Phase 1 Dose-Escalation Study of WVT078, a BCMA×CD3 Bispecific Antibody, in Combination With WHG626, a Gamma-Secretase Inhibitor, in Patients With Relapsed and/or Refractory Multiple Myeloma. Fredrik Schjesvold, Andrew Spencer, Yael C Cohen, Enrique M. Ocio, Jordi Lopez Pardo, Anna Maria Cafro, Natalie S. Callander, Jonathan Kaufman, Meera Mohan, Martin Wermke, Noriko Doki, Rebecca Kan, Karolina Kulec, Gina Trabucco, Stan Ye, Romain Sechaud, Cornelia Quadt, Raghav Chawla, Marc S Raab. Poster Abstract at American Society of Hematology Meeting 2023 (December 9-12, 2023)

54. The Effect of Stem Cell Infusion on Immune Effector Cell Associated Hematotoxicity with BCMA CAR T In Multiple Myeloma. Anannya Patwari MD; Tanvi Patel, MD, Ramya Bachu, MD; Jean Esselmann RN; Lisa E Rein ScM; Aniko Szabo Ph.D.; Abhishek Janardan BA; Vineel Bhatlapenumarthi MD; Evanka Annyapu BS; Catherine Skoog PA, Areyl Goff APRN; Samer Al Hadidi MD; Sharmilan Thanendrarajan MD; Maurizio Zangari MD; Frits van Rhee MD Ph.D.; Binod Dhakal MD, MS; Anita D’Souza MD, MS; Meera Mohan MD, MS; Carolina Schinke MD. Oral Abstract at American Society of Hematology Meeting 2023 (December 9-12, 2023)

55. Racial disparities in autologous stem cell transplant utilization in multiple myeloma persist despite referral to a transplant center. James F. Wu, Noel Estrada-Merly, Binod Dhakal, Meera Mohan, Ravi K. Narra, Marcelo C. Pasquini, Jean Esselmann, Areyl D. Goff, Catharine E. Skoog, Anita D’Souza. Online Abstract at the American Society of Hematology Meeting 2023 (December 9-12, 2023)

56. Does Socioeconomic Deprivation Have an Impact on Light Chain (AL) Amyloidosis Disease and Outcomes? Mingqian Lin, MS1, Aniko Szabo1, Liliana Pezzin1, Jing Dong1, Binod Dhakal1, Meera Mohan1, Ravi Narra1, Marcelo Pasquini1, Anita D’Souza, MD, MS1. Poster abstract at American Society of Hematology Meeting 2023 (December 9-12, 2023)

57. Single Cell Analysis in Long-Term Survivors of Multiple Myeloma Reveals a Novel Cytotoxic Response. Sridhar Rao, Kirthi Pulakanti, Alison Meyer, Atrayee Ray, Karen Carlson, Jennifer Knight, Anita D’Souza, Meera Mohan, Ravi Narra, Marcelo Pasquini, Parameswaran Hari, Siegfried Janz, and Binod Dhakal. Online abstract at American Society of Hematology Meeting 2023 (December 9-12, 2023)

58. Outcomes of Frail Patients Receiving High-Dose Chemotherapy/Autologous stem Cell Transplantation for Multiple Myeloma. Accepted as a poster presentation at the European Society of Blood and Marrow Transplantation, 2024

59. Comparison Of Thiotepa-Based Conditioning Regimens For Older Adults With Primary Central Nervous System Lymphoma Receiving Autologous Hematopoietic Cell Transplantation. Accepted as an oral presentation at the European Society of Blood and Marrow Transplantation, 2024

60. Outpatient Administration of Commercial antiCD19 and antiBCMA Chimeric Antigen Receptor-modified T-cell (CAR-T) Therapies Using a Strategy of No Remote Monitoring and Early Cytokine Release Syndrome (CRS) Intervention. Fateeha Furqan1, Vineel Bhatlapenumarthi1, Timothy S Fenske1, Walter Longo1, Nirav N Shah1, Anita D’Souza1, Marcelo C. Pasquini1, Guru Subramanian Guru Murthy1, Lyndsey Runaas1, Sameem Abedin1, Meera Mohan1, Binod Dhakal1 and Mehdi Hamadani1. Accepted as a poster presentation at the 2024 Tandem Meetings, Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR.

61. Idecabtagene Vicleucel (Ide-Cel) In Patients (Pts) With Clinical High-Risk Early Relapse Multiple Myeloma (Mm) Without Frontline Autologous Stem Cell Transplantation (ASCT): Karmma-2 Cohort 2b. Xavier Leleu, Alfred Chung, Noopur Raje, Meera Mohan, Reuben Benjamin, Adam Sperling, Larry Anderson, Madhav Dhodapkar, Shambavi Richard, Violetta Kivovich,Sarah Johnston, Fan Wu, Debashree Basudhar, Ethan Thompson, Devender Dhanda, Laurie Eliason, Sinhan Tran, Maria Chaudhry, Melissa Alsina. Submitted to European Hematology Association Meeting 2024

62. Immune Prognostic Score Predicts Risk of Infection and Survival Outcomes in Patients with Relapsed Multiple Myeloma Treated with Bispecific Antibodies. Othman Akthar MD1; Aniko Szabo Ph.D.2; Jorge Monge MD2; Danny Luan MD2; Mark Forsberg MD3, Vineel Bhatlapenumarthi MD1; Metodi Balev MD4; Anannya Patwari MD1; Heloise Cheruvalath BS5; Divaya Bhutani MD4; Sharmilan Thanendrarajan MD6; Binod Dhakal MD1; Maurizio Zangari MD6; Tanvi Patel MD 6; Asis Shrestha MD6; Samer Al-Hadidi MD6, Dennis Cooper MD3; Suzanne Lentzsch MD Ph. D 4; Frits van Rhee MD Ph. D 6; Manshi Shah MD7; Anita D’Souza MD1; Carolina Schinke MD6; Rajshekhar Chakraborty MD4; Nishi Shah MD3 ; Meera Mohan MD1. Submitted to American Society of Clinical Oncology Meeting 2024 .